Share-based Payment Arrangement, Expense of Syndax Pharmaceuticals Inc from 31 Dec 2014 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Syndax Pharmaceuticals Inc quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2014 to 30 Sep 2025.
  • Syndax Pharmaceuticals Inc Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $12,082,000, a 1.2% increase year-over-year.
  • Syndax Pharmaceuticals Inc Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $48,546,000, a 24% increase year-over-year.
  • Syndax Pharmaceuticals Inc annual Share-based Payment Arrangement, Expense for 2024 was $43,026,000, a 39% increase from 2023.
  • Syndax Pharmaceuticals Inc annual Share-based Payment Arrangement, Expense for 2023 was $30,951,000, a 93% increase from 2022.
  • Syndax Pharmaceuticals Inc annual Share-based Payment Arrangement, Expense for 2022 was $16,019,000, a 20% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Syndax Pharmaceuticals Inc Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $48,546,000 $12,082,000 +$148,000 +1.2% 01 Jul 2025 30 Sep 2025 10-Q 03 Nov 2025 2025 Q3
Q2 2025 $48,398,000 $13,787,000 +$3,891,000 +39% 01 Apr 2025 30 Jun 2025 10-Q 04 Aug 2025 2025 Q2
Q1 2025 $44,507,000 $10,380,000 +$1,481,000 +17% 01 Jan 2025 31 Mar 2025 10-Q 05 May 2025 2025 Q1
Q4 2024 $43,026,000 $12,297,000 +$3,970,000 +48% 01 Oct 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
Q3 2024 $39,056,000 $11,934,000 +$3,613,000 +43% 01 Jul 2024 30 Sep 2024 10-Q 03 Nov 2025 2025 Q3
Q2 2024 $35,443,000 $9,896,000 +$1,831,000 +23% 01 Apr 2024 30 Jun 2024 10-Q 04 Aug 2025 2025 Q2
Q1 2024 $33,612,000 $8,899,000 +$2,661,000 +43% 01 Jan 2024 31 Mar 2024 10-Q 05 May 2025 2025 Q1
Q4 2023 $30,951,000 $8,327,000 +$4,086,000 +96% 01 Oct 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
Q3 2023 $26,865,000 $8,321,000 +$3,959,000 +91% 01 Jul 2023 30 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 $22,906,000 $8,065,000 +$4,127,000 +105% 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024 2024 Q2
Q1 2023 $18,779,000 $6,238,000 +$2,760,000 +79% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $16,019,000 $4,241,000 +$312,000 +7.9% 01 Oct 2022 31 Dec 2022 10-K 03 Mar 2025 2024 FY
Q3 2022 $15,707,000 $4,362,000 +$981,000 +29% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $14,726,000 $3,938,000 +$698,000 +22% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $14,028,000 $3,478,000 +$711,000 +26% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q4 2021 $13,317,000 $3,929,000 +$1,893,000 +93% 01 Oct 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
Q3 2021 $11,424,000 $3,381,000 +$318,000 +10% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $11,106,000 $3,240,000 +$1,111,000 +52% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 $9,995,000 $2,767,000 +$938,000 +51% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $9,057,000 $2,036,000 +$511,000 +34% 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
Q3 2020 $8,546,000 $3,063,000 +$1,513,000 +98% 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2021 Q3
Q2 2020 $7,033,000 $2,129,000 +$791,000 +59% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $6,242,000 $1,829,000 +$237,000 +15% 01 Jan 2020 31 Mar 2020 10-Q 11 May 2021 2021 Q1
Q4 2019 $6,005,000 $1,525,000 +$52,000 +3.5% 01 Oct 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
Q3 2019 $5,953,000 $1,550,000 -$187,000 -11% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $6,140,000 $1,338,000 -$232,000 -15% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $6,372,000 $1,592,000 +$171,000 +12% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $6,201,000 $1,473,000 +$194,000 +15% 01 Oct 2018 31 Dec 2018 10-K 12 Mar 2021 2020 FY
Q3 2018 $6,007,000 $1,737,000 +$391,000 +29% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019 2019 Q3
Q2 2018 $5,616,000 $1,570,000 +$122,000 +8.4% 01 Apr 2018 30 Jun 2018 10-Q 07 Aug 2019 2019 Q2
Q1 2018 $5,494,000 $1,421,000 +$44,000 +3.2% 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
Q4 2017 $5,450,000 $1,279,000 +$332,000 +35% 01 Oct 2017 31 Dec 2017 10-K 05 Mar 2020 2019 FY
Q3 2017 $5,118,000 $1,346,000 +$554,000 +70% 01 Jul 2017 30 Sep 2017 10-Q 05 Nov 2018 2018 Q3
Q2 2017 $4,564,000 $1,448,000 +$669,000 +86% 01 Apr 2017 30 Jun 2017 10-Q 08 Aug 2018 2018 Q2
Q1 2017 $3,895,000 $1,377,000 -$813,000 -37% 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018 2018 Q1
Q4 2016 $4,708,000 $947,000 -$223,000 -19% 01 Oct 2016 31 Dec 2016 10-K 07 Mar 2019 2018 FY
Q3 2016 $4,931,000 $792,000 -$496,000 -39% 01 Jul 2016 30 Sep 2016 10-Q 08 Nov 2017 2017 Q3
Q2 2016 $5,427,000 $779,000 -$321,000 -29% 01 Apr 2016 30 Jun 2016 10-Q 10 Aug 2017 2017 Q2
Q1 2016 $5,748,000 $2,190,000 +$1,866,000 +576% 01 Jan 2016 31 Mar 2016 10-Q 09 May 2017 2017 Q1
Q4 2015 $3,882,000 $1,170,000 01 Oct 2015 31 Dec 2015 10-K 08 Mar 2018 2017 FY
Q3 2015 $1,288,000 01 Jul 2015 30 Sep 2015 10-Q 14 Nov 2016 2016 Q3
Q2 2015 $1,100,000 01 Apr 2015 30 Jun 2015 10-Q 15 Aug 2016 2016 Q2
Q1 2015 $324,000 01 Jan 2015 31 Mar 2015 10-Q 16 May 2016 2016 Q1

Syndax Pharmaceuticals Inc Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $43,026,000 +$12,075,000 +39% 01 Jan 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
2023 $30,951,000 +$14,932,000 +93% 01 Jan 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
2022 $16,019,000 +$2,702,000 +20% 01 Jan 2022 31 Dec 2022 10-K 03 Mar 2025 2024 FY
2021 $13,317,000 +$4,260,000 +47% 01 Jan 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
2020 $9,057,000 +$3,052,000 +51% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 $6,005,000 -$196,000 -3.2% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
2018 $6,201,000 +$751,000 +14% 01 Jan 2018 31 Dec 2018 10-K 12 Mar 2021 2020 FY
2017 $5,450,000 +$742,000 +16% 01 Jan 2017 31 Dec 2017 10-K 05 Mar 2020 2019 FY
2016 $4,708,000 +$826,000 +21% 01 Jan 2016 31 Dec 2016 10-K 07 Mar 2019 2018 FY
2015 $3,882,000 +$1,625,000 +72% 01 Jan 2015 31 Dec 2015 10-K 08 Mar 2018 2017 FY
2014 $2,257,000 01 Jan 2014 31 Dec 2014 10-K 14 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.